Antihypertensive Effect of Chronic KT3-671, a Structurally New Nonpeptide Angiotensin AT1-Receptor Antagonist, in Stroke-Prone Spontaneously Hypertensive Rats.
-
- Amano Hideto
- Department of Pharmacology, Kyoritsu College of Pharmacy
-
- Fujimoto Kazuko
- Department of Pharmacology, Kyoritsu College of Pharmacy
-
- Suzuki Takeshi
- Department of Pharmacology, Kyoritsu College of Pharmacy
-
- Fujii Takeshi
- Department of Pharmacology, Kyoritsu College of Pharmacy
-
- Mochizuki Seiichiro
- Research Laboratories, Kotobuki Seiyaku Co., Ltd.
-
- Tomiyama Akira
- Research Laboratories, Kotobuki Seiyaku Co., Ltd.
-
- Kawashima Koichiro
- Department of Pharmacology, Kyoritsu College of Pharmacy
この論文をさがす
抄録
KT3-671 (2-propyl-8-oxo-1-[(2’-(1H-tetrazole-5-yl)biphenyl-4-yl)methyl]-4, 5, 6, 7-tetrahydrocycloheptimidazole), a structurally new nonpeptide angiotensin AT1-receptor antagonist, was administered orally and repeatedly to 15-week-old stroke-prone spontaneously hypertensive rats for 7 weeks; and its effects on blood pressure, heart rate, renal function, plasma renin concentration (PRC), plasma aldosterone concentration (PAC) and hypertension-related tissue damage in the brain, heart, kidney and mesenteric artery were investigated. KT3-671 at a dose of 3 or 10 mg/kg, p.o. per day prevented development of hypertension and produced a significant and consistent reduction of blood pressure in a dose-dependent manner. Enalapril at a dose of 10 mg/kg per day produced cardiovascular effects similar to those of KT3-671 at 10 mg/kg. Despite marked reduction in blood pressure, neither KT3-671 nor enalapril affected the heart rate. KT3-671 at 10 mg/kg produced a transient and significant reduction of urinary sodium excretion in the second week, but did not affect renal function at any other time during the experimental period. Both KT3-671 at 10 mg/kg and enalapril at 10 mg/kg produced a significant increase in PRC and showed a tendency to decrease PAC. Repeated administration of KT3-671 reduced the severity of the pathological changes in the kidney. These results suggest that KT3-671 is a potentially useful antihypertensive drug.
収録刊行物
-
- Jpn.J.Pharmacol.
-
Jpn.J.Pharmacol. 69 (3), 215-222, 1995
公益社団法人 日本薬理学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282679263978112
-
- NII論文ID
- 10006063264
-
- NII書誌ID
- AA00691188
-
- COI
- 1:CAS:528:DyaK2MXpsFCjuro%3D
-
- ISSN
- 13473506
- 00215198
-
- PubMed
- 8699629
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可